Pluri Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Pluri hat ein Gesamteigenkapital von $6.6M und eine Gesamtverschuldung von $24.4M, was einen Verschuldungsgrad von 368.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $41.6M bzw. $34.9M.

Wichtige Informationen

368.8%

Verhältnis von Schulden zu Eigenkapital

US$24.40m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$30.62m
Eigenkapital	US$6.62m
Gesamtverbindlichkeiten	US$34.95m
Gesamtvermögen	US$41.56m

Jüngste Berichte zur Finanzlage

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PLURDie kurzfristigen Aktiva des Unternehmens ($32.3M) übersteigen seine kurzfristigen Passiva ($4.5M).

Langfristige Verbindlichkeiten: PLURDie kurzfristigen Vermögenswerte des Unternehmens ($32.3M) übersteigen seine langfristigen Verbindlichkeiten ($30.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PLUR über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: PLURDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 368.8% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: PLUR auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: PLUR verfügt über eine ausreichende Liquiditätsreserve für 1.3 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 2.6% pro Jahr abnimmt.

Pluri Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Pluri Receives Non-Compliance Letter from Nasdaq

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought ₪467k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold ₪5.1m worth of stock

Insider recently sold ₪330k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: ₪17.40

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day low: ₪24.00

Insider recently bought ₪641k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: ₪28.82

Revenue in line with expectations

Insider recently bought ₪629k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought ₪1.1m worth of stock

Full year earnings released - ₪1.60 loss per share

New 90-day high - ₪36.37

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen